ERNA Ernexa Therapeutics Inc.
2.490USD+4.18%Mkt Cap: 4.06M $P/E: —1d ago
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-…
Industry Peers
Biotechnology$127.47BUSDP/E 29.3
$78.65BUSD
$76.14BUSDP/E 18.3
$51.48BUSDP/E 31.2
$48.23BUSDP/E 31.4
$41.82BUSDP/E 17.8
$40.32BUSD
$39.83BUSDP/E 62.6
$32.48BUSDP/E 29.9
$30.04BUSDP/E 37.9
$24.71BUSD
$23.13BUSD
$22.85BUSDP/E 14.4
$22.17BUSDP/E 28.4
$21.94BUSD
$21.10BUSDP/E 29.1
$14.65BUSDP/E 17.1
$14.62BUSDP/E 18.6
$14.44BUSDP/E 15.2
$13.70BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA) Ernexa Therapeutics (NASDAQ:ERNA) shares surged 30% on Wednesday after the company announced positive independent preclinical data supporting its lead cell therapy candidate, ERNA-101, for the treatment of ovarian cancer. Independent research confirms earlier findingsThe company said an independent contract research organisation successfully replicated previous results, demonstrating complete tumour clearance and extended survival in a larger preclinical study. | ||